A Look At Everest Medicines (SEHK:1952) Valuation After Recent Share Price Pullback

Everest Medicines share performance context

Everest Medicines (SEHK:1952) has drawn attention after a sharp share price pullback, with the stock showing a 4.0% decline over the past day and a 32.6% decline over the past 3 months.

See our latest analysis for Everest Medicines.

The recent 4.0% one day share price decline and 15.9% 30 day share price return, combined with a 47.3% 1 year total shareholder return loss, point to fading momentum despite a very large 3 year total shareholder return gain of around 2.2x.

If this kind of volatility has you looking across healthcare, it could be a good moment to see what else is available through 127 healthcare AI stocks.

With Everest Medicines trading at HK$33.02 alongside discounts of around 62% to one intrinsic estimate and 72% to analyst targets, you have to ask: is this a genuine entry point, or is the market already weighing its future growth?

Most Popular Narrative: 63.9% Undervalued

Everest Medicines' most followed narrative puts fair value at HK$91.47, well above the last close at HK$33.02, setting up a very optimistic valuation gap.

Everest's advanced mRNA and in vivo CAR-T platforms, supported by a strong track record in regulatory approvals and robust financial resources, are positioned to capitalize on the surging demand for innovative oncology and autoimmune therapies across Asia's rapidly aging population, offering the potential for substantial future out-licensing opportunities and long-term earnings growth.

Read the complete narrative.

Curious how this story gets to that higher fair value? It leans on rapid revenue expansion, a sharp swing into profitability, and a future earnings multiple that still sits below many biotech peers. The real interest is how those three pieces interact to support HK$91.47 without stretching assumptions too far.

Result: Fair Value of HK$91.47 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, this upbeat story can quickly change if NEFECON and VELSIPITY underperform expectations, or if China pricing and reimbursement pressures tighten faster than analysts model.

Find out about the key risks to this Everest Medicines narrative.

Next Steps

If this mix of optimism and risk feels finely balanced, it is worth checking the underlying data now and deciding where you stand. To see what those optimistic points actually are, take a closer look at the 3 key rewards.

Ready to find your next idea?

If Everest Medicines has your attention, do not stop here. Use the Simply Wall Street Screener to quickly surface fresh ideas that match your style and risk comfort.

• Target dependable income by reviewing companies in the 473 dividend fortresses that could suit a portfolio focused on regular cash returns.
• Hunt for value by checking the screener containing 590 high quality undiscovered gems that may not yet be on everyone else's radar but still pass solid fundamental tests.
• Prioritise resilience by scanning the 285 resilient stocks with low risk scores if you want businesses that score well on financial strength and risk checks.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com